Analytical Data
-
基因名
KCNC3
- Application
-
别名
KCNC3; Potassium voltage-gated channel subfamily C member 3; KSHIIID; Voltage-gated potassium channel subunit Kv3.3
-
种属
Human
-
表达系统
E. coli
-
标签
GST-tag at N-terminal
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q14003
-
表达区间
671-757aa
-
氨基酸序列
ALAHEDCPAIDQPAMSPEDKSPITPGSRGRYSRDRACFLLTDYAPSPDGSIRKATGAPPLPPQDWRKPGPPSFLPDLNANAAAWISP
-
分子量
35.31 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
KCNC3, a member of the potassium channel family, encodes for the voltage-gated K channels and plays a crucial role in the regulation of membrane potential and neuronal excitability. Mutations in the KCNC3 gene have been linked to a rare neurological disorder known as Spinocerebellar Ataxia type 13 (SCA13), characterized by progressive ataxia and other motor coordination issues. The study of KCNC3 recombinant protein is significant as it helps in elucidating the functional properties of the channel, including its ion selectivity, gating kinetics, and interaction with other cellular proteins. Understanding the structure and function of KCNC3 is essential for developing targeted therapies for SCA13 and other related disorders. Research involving recombinant KCNC3 protein can enhance our comprehension of potassium channelopathies and contribute to innovations in drug design and molecular therapies that aim to correct the dysfunctional signaling pathways resulting from KCNC3 mutations. As scientists continue to analyze the protein's behavior in various cellular contexts, it holds the promise of advancing our knowledge of not only KCNC3-related pathologies but also the broader implications of potassium channels in health and disease.
